Yann Mazabraud - 14 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of International
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud
Issuer symbol
RYTM
Transactions as of
14 Feb 2026
Net transactions value
$0
Form type
4
Filing time
18 Feb 2026, 16:30:22 UTC
Previous filing
13 Feb 2026
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mazabraud Yann EVP, Head of International 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud 18 Feb 2026 0001774702

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +10,000 +23% 53,155 14 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -10,000 -25% $0.000000 30,000 14 Feb 2026 Common Stock 10,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.